EUVIMEDEUVIMED entdecken
Open Access

Antimitochondrial antibodies in systemic lupus erythematosus are associated with and predict nephritis, arterial vascular events, and mortality

Yann L C Becker, Éric Boilard, Emmanuelle Rollet-Labelle, Christian Lood, Anne-Sophie Julien, Michal Abrahamowicz, Isabelle Allaeys, May Choi, Joannie Leclerc, Tania Lévesque, Murray Urowitz, John G Hanly und 31 weitere

Annals of the Rheumatic Diseases · 2026

DOI: 10.1016/j.ard.2025.11.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026. Verfasst von Yann L C Becker und 42 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche ARThrite-Université Laval, Quebec City, QC, Canada; Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québ…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Autoantibodies, Lupus Nephritis, Mitochondria. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAMS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Systemic lupus erythematosus (SLE) remains a deadly disease, yet our ability to predict adverse outcomes is poor. Mitochondria are organelles recognised by the immune system when released from cells, and antimitochondrial antibodies (AMA) can be detected in people with SLE. We assessed AMA as markers of nephritis, arterial vascular events (AVE), and other outcomes including mortality. METHODS: We studied sera and data from 1114 participants of the Systemic Lupus International Collaborating Clinics inception cohort. We measured antiwhole mitochondria (AwMA), antimitochondrial DNA (AmtDNA), and antimitochondrial RNA (AmtRNA) antibodies by direct Enzyme-Linked ImmunoSorbent Assays (ELISAs). Separate multivariable Cox proportional hazards regression models estimated associations of either baseline or most recent measures of AMA with the outcomes, adjusted for biological sex, age, medications, and other clinical factors. Interactions of AMA with biological sex were tested for each outcome. RESULTS: All AMA titres were elevated in SLE vs healthy individuals. Higher AMA levels were associated with a higher hazard of nephritis, with the strongest associations for most recent AmtDNA (adjusted hazard ratio [aHR] =1.61 for increase of 1 SD, 95% CI 1.43-1.82) and AmtRNA (aHR =1.59, 1.46-1.73). Higher baseline AwMA levels predicted early mortality (aHR =1.19, 1.02-1.40). Most recent AmtDNA (aHR =1.68, 1.28-2.19) was associated with higher mortality throughout the follow-up. For AVE, the impact of higher AmtRNA was stronger in females. CONCLUSIONS: Baseline and most recent assessments of AMA levels may help identify individuals at higher risk of severe outcomes in SLE, including mortality. Integrating AMA into precision medicine strategies will allow deeper exploration of lupus heterogeneity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicAutoantibodiesLupus NephritisMitochondriaHumansFemaleMaleAdultMiddle AgedBiomarkersDNA, MitochondrialProportional Hazards ModelsPrognosis

Substanzen

AutoantibodiesBiomarkersDNA, Mitochondrial

Autor:innen und Institutionen

  • Centre de Recherche ARThrite-Université Laval, Quebec City, QC, Canada; Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Quebec City, QC, Canada.
  • Division of Rheumatology, University of Washington, Seattle, WA, USA.
  • Department of Mathematics and Statistics, Université Laval, Québec City, QC, Canada.
  • Department of Epidemiology & Biostatistics, McGill University, Montréal, Québec City, QC, Canada.
  • Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
  • Centre de Recherche ARThrite-Université Laval, Quebec City, QC, Canada.

Förderung

  • NHLBI NIH HHS
  • NIAMS NIH HHS
  • National Institutes of Health
  • Santé
  • National Research Foundation of Korea
  • Ministry of Education
  • Canadian Institutes of Health Research

Zitieren

APA

Becker, Y. L. C., Boilard, É., Rollet-Labelle, E., Lood, C., Julien, A. S., Abrahamowicz, M., Allaeys, I., Choi, M., Leclerc, J., Lévesque, T., Urowitz, M., Hanly, J. G., Gordon, C., Bae, S. C., Romero-Diaz, J., Sanchez-Guerrero, J., Clarke, A. E., Bernatsky, S., Wallace, D., …, & Fortin, P. R. (2026). Antimitochondrial antibodies in systemic lupus erythematosus are associated with and predict nephritis, arterial vascular events, and mortality. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.11.007

Vancouver

Becker YLC, Boilard É, Rollet-Labelle E, Lood C, Julien AS, Abrahamowicz M, et al. Antimitochondrial antibodies in systemic lupus erythematosus are associated with and predict nephritis, arterial vascular events, and mortality. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2025.11.007

BibTeX
@article{Becker2026,
  author = {Becker, Yann L C and Boilard, Éric and Rollet-Labelle, Emmanuelle and Lood, Christian and Julien, Anne-Sophie and Abrahamowicz, Michal and Allaeys, Isabelle and Choi, May and Leclerc, Joannie and Lévesque, Tania and Urowitz, Murray and Hanly, John G and Gordon, Caroline and Bae, Sang-Cheol and Romero-Diaz, Juanita and Sanchez-Guerrero, Jorge and Clarke, Ann E and Bernatsky, Sasha and Wallace, Daniel and Isenberg, David and Rahman, Anisur and Merrill, Joan and Gladman, Dafna D and Bruce, Ian N and Petri, Michelle and Ginzler, Ellen and Dooley, Mary Anne and Ramsey-Goldman, Rosalind and Manzi, Susan and Jönsen, Andreas and Alarcόn, Graciela S and van Vollenhoven, Ronald and Aranow, Cynthia and Ruiz-Irastorza, Guillermo and Lim, Sam and Inanc, Murat and Kalunian, Kenneth and Jacobsen, Soren and Peschken, Christine and Kamen, Diane and Askanase, Anca and Buyon, Jill and Fortin, Paul R},
  title = {Antimitochondrial antibodies in systemic lupus erythematosus are associated with and predict nephritis, arterial vascular events, and mortality},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  doi = {10.1016/j.ard.2025.11.007}
}
Kostenlos starten →